Maddyness

uMotif raises £5M to power clinical trials and deliver therapies faster

Comments
Share :
Up
Previous part
1 —
Next part
Down
Maddyness
Up
Menu
Part 1
Down
Finance

uMotif raises £5M to power clinical trials and deliver therapies faster

Credits: © uMotif
60 - trending  |  
Comments
By Maddyness - 08 September 2020 / 07H00 - Updated 03 September 2020

Founded in 2012 in London, uMotif's robust and scalable cloud-based platform is trusted by the world’s leading pharmaceutical and biotech companies to capture clinical research data.

The funding, which also saw participation from Oslo-based DNV-GL and existing angel investors, will fuel further development of uMotif’s patient-centric and decentralised approach to clinical studies and enable expansion into new study types and more high-demand territories. Helping get much-needed, and at times life-saving, therapies to patients faster.

“We’re excited to help our customers implement patient-centred research designs by using the uMotif platform to capture high-quality data. This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster.” – Bruce Hellman, CEO and Co-Founder of uMotif

Life sciences companies are increasingly embracing decentralised and virtual study designs – where patient consent and data is captured using their own devices from wherever they are located. This is in stark contrast to the centralised, inconvenient and complex studies in which patients have to go to a site, such as a hospital, to submit their data. A trend that has been further driven by COVID-19.

UMotif powers innovative decentralised and patient-centric approaches that increase patient engagement, improving the chances of the study’s success, reducing the burden on participants, and helping to reach new patient populations and increase study diversity.

“Now more than ever, having access to reliable patient data during clinical trials is crucial. uMotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants. It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients.” – Dr. Andrew Elder, Deputy Managing Partner at AlbionVC

UMotif’s robust and scalable cloud-based platform is trusted by the world’s leading pharmaceutical and biotech companies to capture clinical research data, and its strengths lie in the way it works with and keeps thousands of research participants engaged. With studies taking place in 26 countries from clinical to real-world settings, and across more than 25 therapeutic areas – from dermatology and rare disease to oncology and cardiology, uMotif’s focus is to foster a highly engaging patient experience to capture larger volumes of higher quality data.

New funding will further enhance uMotif’s highly configurable software platform to support existing studies and support new study designs. With a customer base spanning Europe and the US, the investment will drive continued commercial growth and enable further geographical expansion.

“Healthcare is dependent on digital transformation if it is to move towards being a more sustainable sector. uMotif has developed a digital platform that can support new models of clinical trials while also ensuring that the patient voice is heard. We have been impressed with the platform and the management team at uMotif who are responsive to customer and patient needs and passionate about making a difference.” – Kaare Helle, Venture Director at DNV GL

Read also
By

Maddyness

08 September 2020 / 07H00
Updated 03 September 2020
Most read articles of the moment

Invest with impact, purpose and meaning to manage your “wealthbeing”

Entrepreneurs
By Maddyness, with HSBC Global Private Banking - 07H00Monday 21 September 2020
Next

Is Emotional Intelligence the number one leadership trait?

Business
By Cleo McGee - 07H10Wednesday 16 September 2020
Next

Do you know where your pension is invested?

Business
By Florence Wildblood - 07H00Thursday 24 September 2020
Next

COVID-19: Interview with Greg Watts, Founder & CEO of Findr

Business
By Greg Watts - 07H00Wednesday 16 September 2020
Next

Lockdown has made us rethink how we get around

Innovation
By Florence Wildblood - 07H03Friday 25 September 2020
Next

COVID-19: Interview with Ronan Finnegan, Co-Founder of SPACEbands

Entrepreneurs
By Ronan Finnegan - 07H00Wednesday 23 September 2020
Next
Business
Menu
Entrepreneurs
Menu
Finance
Menu
Innovation
Menu
Technology
Menu
Agenda
Calendar
MaddyEvent
MaddyEvent
MaddyStudio
MaddyStudio
Search
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Most viewed articles
Newsletter
About
Legal Information
Search
Our services
Categories
Maddynews
Hmm ... There's a problem :(
Maddyness

Comme vous le savez, Maddyness est à la pointe de l'innovation.
Malheureusement il semble que votre navigateur ne le soit pas encore...

Pour une bonne expérience de navigation
(et être au top de la modernité) pensez à passer sur :
Chrome
Chrome
Safari
Safari
Firefox
Firefox
Edge
Edge